- Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
- Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
- Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
- Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
Key statistics
On Thursday, Revance Therapeutics Inc (RVNC:NMQ) closed at 22.23, -25.90% below its 52-week high of 30.00, set on Sep 27, 2021.
52-week range
Markit short selling activity
Open | 21.60 |
---|---|
High | 22.60 |
Low | 21.42 |
Bid | -- |
Offer | -- |
Previous close | 22.23 |
Average volume | 907.10k |
---|---|
Shares outstanding | 72.77m |
Free float | 70.35m |
P/E (TTM) | -- |
Market cap | 1.57bn USD |
EPS (TTM) | -3.84 USD |
Data delayed at least 15 minutes, as of Aug 18 2022 21:00 BST.
More ▼